Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
News|Videos|November 17, 2026

One Injection a Month: Efimosfermin Takes Aim at Cirrhosis in MASH

Mazen Noureddin, MD, MHSc, discusses phase 2 data for GSK’s once-monthly efimosfermin presented at The Liver Meeting 2026, including fibrosis marker results in patients with compensated cirrhosis.

GSK presented new phase 2 data for efimosfermin at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2026, held November 5–9 in Denver, Colorado.¹ Efimosfermin is an investigational long-acting variant of fibroblast growth factor 21 (FGF21), given as a once-monthly subcutaneous injection. It is being developed for metabolic dysfunction-associated steatohepatitis (MASH), particularly in patients with advanced disease or at high risk of progression who have limited or no approved treatment options.¹ The therapy has received Breakthrough Therapy Designations from the US FDA and China’s CDE, as well as Priority Medicines (PRIME) designation from the European Medicines Agency, for MASH.¹

In a video interview with BioPharm International®, Mazen Noureddin, MD, MHSc, a hepatologist and professor of medicine at Houston Methodist Hospital and chief scientific officer of Summit Clinical Research Solutions, said the FGF21 class has shown improvements in both steatohepatitis and fibrosis within 24 weeks in phase 2 studies.

“So [there’s a] quick, potent, and lasting effect of this drug class,” Noureddin said. “And hepatologists are looking forward to it.”

He added that monthly dosing sets efimosfermin apart from other injectable therapies. GSK has said the molecule’s low immunogenicity and extended half-life make a monthly regimen possible.⁴ “No one really wants to inject that often, right?” Noureddin said. “So daily versus weekly, people prefer weekly. And, ideally, people prefer monthly.”

What did the phase 2 data show in patients with cirrhosis?

The new data build on a 24-week, randomized, placebo-controlled phase 2 trial in patients with MASH and F2 or F3 fibrosis, published in The Lancet in February 2026.² Noureddin noted that 45% of patients receiving efimosfermin achieved fibrosis improvement, compared with 21% receiving placebo, and 68% achieved MASH resolution, compared with 29% receiving placebo.²

At AASLD, Noureddin presented results from a separate open-label cohort of 39 patients (poster #2299). Twenty-four had F2 or F3 fibrosis, and 15 had compensated cirrhosis (F4). Patients received once-monthly efimosfermin at 225 mg or 300 mg for 48 weeks, with follow-up to 52 weeks. Liver stiffness, enhanced liver fibrosis (ELF) score, and PRO-C3 all decreased through 52 weeks, including in patients with compensated cirrhosis.³

“And importantly, the pharmacokinetics were similar in the F2/F3 and F4 population with no serious adverse events related to the drug,” Noureddin said.

A second analysis (poster #5025) examined whether reductions in liver fat measured by MRI proton density fat fraction (MRI-PDFF) track with histological fibrosis improvement in patients with F2 or F3 fibrosis.¹ Noureddin described liver fat as a pharmacodynamic biomarker. In about 62 patients treated for 24 weeks, he said, efimosfermin produced a relative liver fat reduction of about 34% compared with placebo, and larger reductions were associated with greater fibrosis improvement.

“So usually when you see that in phase 2 trial with a smaller sample size, it’s highly likely that you’ll see it in the phase 3 study,” he said.

On safety, Noureddin contrasted FGF21 therapies with glucagon-like peptide-1 (GLP-1) receptor agonists, which are often limited by nausea, vomiting, and diarrhea. “They do have GI side effects, but not even comparable to the GLP-1,” he said. In the Lancet trial, adverse events occurred in 67% of patients receiving efimosfermin and 55% of those receiving placebo. The most frequent were gastrointestinal events, which were transient and occurred within the first few weeks of treatment.² Noureddin added that bone biomarkers did not change over 1 year of treatment, a question that has followed the FGF21 class.

Efimosfermin is now being evaluated in the phase 3 ZENITH trials in patients with F2 or F3 fibrosis and the phase 3 NEBULA trials in patients with compensated cirrhosis.¹ No therapies are currently approved for more advanced forms of MASH.¹

Noureddin said the NEBULA trials target a population with no approved options. “We don’t have approved therapies for the cirrhotics as yet,” he said.

References

  1. GSK. GSK showcases progress in liver portfolio at AASLD 2026. Press release. Published November 5, 2026. Accessed November 13, 2026.
  2. Noureddin M, Kowdley KV, Odrljin T, et al. Efimosfermin alfa (BOS-580) once per month in people with metabolic dysfunction-associated steatohepatitis with F2 or F3 fibrosis: results from a 24-week, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2026;407(10530):794-804. doi:10.1016/S0140-6736(25)02276-7
  3. HCPLive. Once-monthly efimosfermin improves fibrosis markers in phase 2 MASH study. Published November 6, 2026. Accessed November 13, 2026.
  4. GSK. GSK to acquire efimosfermin, a phase III-ready potential best-in-class specialty medicine to treat and prevent progression of steatotic liver disease (SLD). Press release. Published May 2025. Accessed November 13, 2026.

About the Speaker

Mazen Noureddin, MD, MSHc

Dr. Noureddin is a professor of medicine at Houston Methodist Hospital and an internationally recognized leader in steatotic liver disease (SLD) and SLD-related cirrhosis. He founded the Houston Research Institute and serves as chief scientific officer and co-chairman of the board of Summit Clinical Research Solutions. He has led or participated in more than 100 clinical trials, holds an NIDDK R01 award, and has authored more than 350 peer-reviewed publications. In 2026, he received AASLD’s inaugural Impact Award.


Related to this article